Pathological complete response, which is the absence of invasive residual tumour cells in the breast and axillary lymph nodes, is strongly associated with improved disease-free and overall survival, especially in the more aggressive subtypes of HER2-positive and triple-negative breast cancer [4]. Here, ERBB2 is linked to triple-negative breast carcinoma.